ProMetic Life Sciences Inc. was a Canadian-headquartered biopharmaceutical corporation with a dual business model that spanned two core areas of the life sciences industry: bioseparations technology and the development of novel therapeutic products, including both small-molecule drugs and plasma-derived therapeutics. The company, which was based in Laval, Quebec, established a global presence with R&D and manufacturing facilities in the UK and business activities across the U.S., Europe, and Asia. The organization's history is characterized by its foundational expertise in protein purification technologies and a later strategic pivot toward the clinical development of proprietary drug candidates, particularly those targeting rare and unmet medical needs.
Business Activities and Core Competencies
ProMetic's operational focus was divided into two primary segments that leveraged its core scientific expertise:
1. Bioseparations and Affinomics Technology
This segment formed the foundation of ProMetic's commercial operations and generated recurrent revenue through the supply of advanced purification technologies.
Affinity Chromatography Media: The company was a major supplier of affinity chromatography media, which is essential for the large-scale purification of biological molecules (biologics) and drug development. ProMetic's proprietary affinity technology was globally recognized and offered to industry leaders for applications including proteomics, large-scale purification of biologics, and the elimination of pathogens.
Plasma Protein Purification System (PPPS???): A key technological offering was the Plasma Protein Purification System (PPPS???). This proprietary technology provided a competitive advantage by enabling the highly efficient, multi-product extraction and purification of multiple therapeutic proteins from human plasma. The system was designed to increase the yield of therapeutic products from a single batch of plasma while concurrently providing pathogen reduction capabilities, including prion capture technology.
Services: In addition to its media products, the company operated a contract development and manufacturing operation (CDMO) in the United Kingdom and offered services such as technology transfer and skills training to clients utilizing its protein technologies.
2. Novel Therapeutics and Drug Development
The second core business activity involved the discovery and clinical development of proprietary small-molecule and plasma-derived drug candidates aimed at high-value, unmet medical needs, with a significant focus on orphan diseases.
Small-Molecule Drug Pipeline: ProMetic developed a broad pipeline of novel small-molecule therapeutics. The research was differentiated, involving the study of G-protein-coupled-receptors (GPRs), specifically GPR40, GPR120, and GPR84, known as free fatty acid receptors (FFAR's). These drug candidates were engineered to act with a multiple mode-of-action, for example as agonists (stimulators) of GPR40 and GPR120, and antagonists (inhibitors) of GPR84. The primary therapeutic focus included:
Fibrosis and Organ Disease: Targeting conditions like pulmonary fibrosis, chronic kidney disease, and other organ dysfunction, the company's anti-fibrotic program was a significant focus.
Orphan Diseases: The pipeline addressed rare or orphan diseases, particularly those affecting the liver, respiratory system, and kidneys.
Specific Candidates:
PBI-4050: The lead small-molecule drug candidate, which was expected to enter Phase 3 clinical studies for the treatment of Alström Syndrome, a rare genetic disorder.
PBI-4547: A second drug candidate that was planned to enter Phase 1 clinical studies.
Plasma-Derived Therapeutics: Leveraging its core expertise in plasma purification, the company also developed its own plasma-derived therapeutic products.
Ryplazim??? (plasminogen): This was the lead plasma-derived therapeutic product, developed for the treatment of patients with congenital plasminogen deficiency (CPD), a rare condition that can lead to blindness and respiratory failure. The company successfully advanced this product through regulatory processes, and it was later acquired by another entity, becoming the first FDA-approved treatment for CPD.
Corporate Evolution
ProMetic Life Sciences Inc. underwent significant corporate restructuring and strategic changes toward the end of its operation under that name. In 2019, the company announced its intention to change its name to Liminal BioSciences Inc. to reflect a new vision and strategic focus on its novel small-molecule and plasma-derived therapeutics pipeline for rare and orphan diseases. Subsequently, the "Prometic life sciences business," including the key plasma purification plant in Laval, Quebec, and the license for Ryplazim®, was acquired by Kedrion in 2021, marking a key divestiture of the bioseparations and plasma-derived therapeutics assets.
Please note: This information is generated by AI. For legal use, verify with company sources.
